ACAT2 and prostate adenocarcinoma: Conversely, ACAT2 manifested low expression in stomach adenocarcinoma (STAD), head‐and‐neck squamous cell carcinoma (HNSC), prostate adenocarcinoma (PRAD), and liver hepatocellular carcinoma (LIHC).